# A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)

> **NCT04702997** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 81 (actual)

## Conditions studied

- Chronic Kidney Diseases

## Interventions

- **DRUG:** Bardoxolone methyl oral capsule
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT04702997
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-09
- **Primary completion:** 2021-10-20
- **Final completion:** 2021-11-23
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04702997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04702997, "A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04702997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*